Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Jun 27, 2003 9:21pm
320 Views
Post# 6207588

RE: bilosellhi must be from Missouri

RE: bilosellhi must be from Missouriproboscis i have a healthy dose of skepticsim, others who have a much more optimistic bent, who take offense to someone who points out that their fantasies of $100 share price might be a bit premature, might see me as a basher, so be it. i'm not one to mind ignores from the ignorant. i think my posting history has shown that i will acknowledge when i've erred - and i've been willing to put my money and onc shares behind my posts - something that i haven't seen from too many others here. regarding promotion, if there are still survivors from the first phase I trial still alive, or for that matter ph II glio patients, who shouldn't be based on their prognosis prior to treatment with reolysin, that would be newsworthy and something that should be communicated officially and regularly updated by onc. i know in the past there have been reasons given that they can't disclose results because of patient confidentiality, etc., but i don't see how providing periodic updates on the status of patients as a group violates an individual's privacy or misrepresents the facts, if in fact, those patients are surviving beyond expected timeframes. its almost like these guys are trying to keep this a big secret for some unknown reason. i understand people might not like having such inconsistencies pointed out, but to try to discredit the messenger - well, they only discredit themselves in the attempt. carry on
Bullboard Posts